Intermediates useful in the synthesis of alkylquinoline and...

Details Intermediates useful in the synthesis of alkylquinoline and... Intermediates useful in the synthesis of alkylquinoline and...

2006-06-06

2010-11-02

Wilson, James O (Department: 1624)

Organic compounds -- part of the class 532-570 series

Organic compounds

Nitrogen attached directly or indirectly to the purine ring...

C546S152000, C546S153000

Reexamination Certificate

active

07825244

ABSTRACT:
The invention is directed to alkylquinoline and alkylquinazoline compounds of Formula C:wherein R1, R2, R99, and X are as defined herein, the use of such compounds in the synthesis of protein tyrosine kinase inhibitors, particularly inhibitors of FLT3 and/or c-kit and/or TrkB.

REFERENCES:
patent: 3517005 (1970-06-01), Cronin et al.
patent: 4001422 (1977-01-01), Danilewicz et al.
patent: 4542132 (1985-09-01), Campbell et al.
patent: 5300515 (1994-04-01), Takano et al.
patent: 5474765 (1995-12-01), Thorpe
patent: 5762918 (1998-06-01), Thorpe
patent: 5855866 (1999-01-01), Thorpe et al.
patent: 5866562 (1999-02-01), Schohe-Loop et al.
patent: 5948786 (1999-09-01), Fujiwara et al.
patent: 6342219 (2002-01-01), Thorpe et al.
patent: 6613772 (2003-09-01), Schindler et al.
patent: 6776796 (2004-08-01), Falotico et al.
patent: 7074801 (2006-07-01), Yoshida et al.
patent: 2002/0016625 (2002-02-01), Falotico et al.
patent: 2004/0049032 (2004-03-01), Charrier et al.
patent: 2006/0281772 (2006-12-01), Baindur et al.
patent: 08/82717 (1998-12-01), None
patent: 1 566 379 (2005-08-01), None
patent: 2295387 (1996-05-01), None
patent: 59076082 (1984-04-01), None
patent: WO 96/09294 (1996-03-01), None
patent: WO 96/32907 (1996-10-01), None
patent: WO 97/28118 (1997-08-01), None
patent: WO 97/38992 (1997-10-01), None
patent: WO 99/31086 (1999-06-01), None
patent: WO 00/13681 (2000-03-01), None
patent: WO 01/32632 (2001-05-01), None
patent: WO 02/16360 (2002-02-01), None
patent: WO 02/16362 (2002-02-01), None
patent: WO 02/32861 (2002-04-01), None
patent: WO 02/48152 (2002-06-01), None
patent: WO 02/069972 (2002-09-01), None
patent: WO 02/088107 (2002-11-01), None
patent: WO 02/092599 (2002-11-01), None
patent: WO 03/024931 (2003-03-01), None
patent: WO 03/024969 (2003-03-01), None
patent: WO 03/035009 (2003-05-01), None
patent: WO 03/037347 (2003-05-01), None
patent: WO 03/057690 (2003-07-01), None
patent: WO 03/064413 (2003-08-01), None
patent: WO 03/099771 (2003-12-01), None
patent: WO 2004/002960 (2004-01-01), None
patent: WO 2004/005281 (2004-01-01), None
patent: WO 2004/016597 (2004-02-01), None
patent: WO 2004/018419 (2004-03-01), None
patent: WO 2004/039782 (2004-05-01), None
patent: WO 2004/043389 (2004-05-01), None
patent: WO 2004/046120 (2004-06-01), None
patent: WO 2004/058727 (2004-07-01), None
patent: WO 2004/058749 (2004-07-01), None
patent: WO 2004/071460 (2004-08-01), None
patent: WO 2005/021500 (2005-03-01), None
patent: WO 2005/037825 (2005-04-01), None
patent: WO 2005/051304 (2005-06-01), None
patent: WO 2006/135646 (2006-12-01), None
patent: WO 2006/135721 (2006-12-01), None
Baran, P. et. al., “Total synthesis of marine natural products without using protecting groups”. Nature, vol. 446, Mar. 22, 2007, pp. 404-408.
Nomoto et al., Chemical & Pharmaceutical Bulletin (1990), 38(11), 3014-19.
Ivan, Marius G. et al. Photochemistry and Photobiology (2003), 78(4), 416-419.
Sadykov, T. et al. Khimiya Geterotsiklicheskikh Soedinenii (1985), (4), 563.
Erzhanov, K. B. et al. Zhurnal Organicheskoi Khimii (1989), 25(8), 1729-32.
Fujiwara, Norio et al. Bioorganic & Medicinal Chemistry Letters (2000), 10(12), pp. 1317-1320.
Takai, Haruki et al. Chemical & Pharmaceutical Bulletin (1986), 34(5), 1907-16.
Liotta et al., Nature, Aug. 26, 2004; 430(7003), pp. 973-974.
Jaboin et al., Cancer Lett. Apr. 10, 2003;193(1), pp. 109-114.
Ashman, L., Int J Biochem Cell Biol. (1999);31(10), pp. 1037-1051.
Sattler et al., Leuk Res. (2004), 28 Suppl 1, pp. S11-20.
Advani, A., Curr Hematol Rep. (2005), 4(1), pp. 51-58.
McKenna, Hilary J. et al. Mice lacking flt3 ligand have deficient hematopoiesis affecting hematopoietic progenitor cells, dendritic cells, and natural killer cells. Blood. Jun. 2000; 95(11), pp. 3489-3497.
Drexler, H. G. and H. Quentmeier (2004), “FLT3: receptor and ligand”, Growth Factors, (2004) 22(2), pp. 71-73.
Stirewalt, D. L. and J. P. Radich,(2003), “The role of FLT3 in haematopoietic malignancies”, Nat Rev Cancer, (2003), 3(9): 650-65.
Scheijen, B. and J. D. Griffin, (2002), “Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease”, Oncogene, (2002), 21(21), pp. 3314-3333.
Kottaridis, P. D., R. E. Gale, et al. (2003), “Flt3 mutations and leukaemia”, Br J Haematol (2003), 122(4), pp. 523-538.
Ansari Lari, Ali et al., FLT3 mutations in myeloid sarcoma, British Journal of Haematology. Sep. 2004 126(6), pp. 785-791.
Gilliliand et al., Blood, (2002), vol. 100, pp. 1532-1542.
Levis, M., K. F. Tse, et al., 2001, “A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.” Blood (2001), 98(3), pp. 885-887.
Tse KF, et al. Inhibition of FLT3 mediated transformation by use of a tyrosine kinase inhibitor. Leukemia. Jul. 2001; 15(7), pp. 1001-1010.
Smith, B. Douglas et al., Single agent CEP 701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia, Blood, May 2004; 103(10), pp. 3669-3676.
Griswold, Ian J. et al. Effects of MLN518, A Dual FLT3 and KIT Inhibitor, on Normal and Malignant Hematopoiesis. Blood, Jul. 2004, 104: 2912-2918.
Yee, Kevin W. H. et al., SU5416 and SU5614 inhibit kinase activity of wild type and mutant FLT3 receptor tyrosine kinase, Blood, Sep. 2002; 100(8), pp. 2941-2949.
O'Farrell, Anne Marie et al., SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo, Blood, May (2003); 101(9), pp. 3597-3605.
Stone, R.M. et al., PKC 412 FLT3 inhibitor therapy in AML: results of a phase II trial, Ann Hematol. (2004); 83 Suppl 1, pp. S89-90.
Murata, K. et al., Selective cytotoxic mechanism of GTP 14564, a novel tyrosine kinase inhibitor in leukemia cells expressing a constitutively active Fms like tyrosine kinase 3 (FLT3), J Biol Chem. Aug. 29, 2003; 278(35), pp. 32892-32898.
Levis, Mark et al., Novel FLT3 tyrosine kinase inhibitors, Expert Opin. Investing. Drugs (2003) 12(12), pp. 1951-1962.
Levis, Mark et al., Small Molecule FLT3 Tyrosine Kinase Inhibitors, Current Pharmaceutical Design, (2004), 10, pp. 1183-1193.
Gould, P., International J. Pharm. (1986), 33, pp. 201-217.
Berge et al., J. Pharm. Sci., Jan. 1977, 66(1), pp. 1-19.
Boothroyd et al., Tet Lett (1995), 36(14), pp. 2411-2414.
Sitzmann et al., J. Org Chem, (1985), 50, pp. 5879-5881.
Tyrrell et al., Synthesis, (2004), 4, pp. 469-483.
Kristensen et al., Organic Letters, (2001), 3(10), pp. 1435-1437.
Stevenson et al., J. Org. Chem., (1986), 51, pp. 616-620.
Hall et al., Inorganic Chemistry (1997), 36(14), pp. 3096-3101.
Bertani et al., Organometallics, (1996), 15(4), pp. 1236-1241.
Quentmeier H, Reinhardt J, Zaborski M, Drexler HG, FLT3 mutations in acute myeloid leukemia cell lines, Leukemia, (2003), 17, pp. 120-124.
Sadick, MD et al., Analysis of Heregulin-Induced ErbB2 Phosphorylation with a High-Throughput Kinase Receptor Activation Enzyme-Linked Immunsorbent Assay, Analytical Biochemistry, (1996), 235, pp. 207-214.
Baumann CA et al., Development of a quantitative, high-throughput cell-based enzyme-linked immunosorbent assay for detection of colony-stimulating factor-1 receptor tyrosine kinase inhibitors, J Biochem Biophys Methods, (2004), 60, pp. 69-79.
Libby P, “Vascular biology of atherosclerosis: overview and state of the art”, Am J Cardiol (2003), 91(3A), pp. 3A-6A.
Helisch A, Schaper W., Arteriogenesis: the development and growth of collateral arteries. Microcirculation, (2003),10(1), pp. 83-97.
Holz FG et al.,“Pathogenesis of lesions in late age-related macular disease”, Am J Ophthalmol. (2004), 137(3), pp. 504-510.
Schiele TM et. al.,“Vascular restenosis—striving for therapy.” Expert Opin Pharmacother. (2004), 5(11), pp. 2221-2232.
Thannickal VJ et al., Idiopathic pulmonary fibrosis: emerging concepts on pharmacotherapy, Expert Opin Pharmacother. (2004), 5(8), pp. 1671-1686.
Cybulsky AV, “Growth factor pathways in proliferative glomerulonephritis”, Cur

Affiliated with

Also associated with

Rating

Intermediates useful in the synthesis of alkylquinoline and... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Intermediates useful in the synthesis of alkylquinoline and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Intermediates useful in the synthesis of alkylquinoline and... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4238553